Applies to the following strength(s): 300 mg ; 400 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Myeloma
10 mg/kg IV every week for the first 2 cycles and every 2 weeks thereafter
Manufacturer recommended infusion rate for elotuzumab:
CYCLE 1, DOSE 1:
-Time interval 0 to 30 min; Rate 0.5 mL/min
-Time interval 30 to 60 min; Rate 1 mL/min
-Time interval 60 min or more; Rate 2 mL/min
CYCLE 1, DOSE 2:
-Time interval 0 to 30 min; Rate 1 mL/min
-Time interval 30 min or more; Rate 2 mL/min
CYCLE 1, DOSE 3 AND 4 AND ALL SUBSEQUENT CYCLES:
-Rate 2 mL/min
-The length of a cycle is 28 days.
-This drug is given in combination with lenalidomide and dexamethasone.
-Patients should be premedicated 45 to 90 minutes before administration of this drug with dexamethasone, diphenhydramine (or equivalent H1 blocker), ranitidine (or equivalent H2 blocker), and acetaminophen. Consult manufacturer product information or local protocol for instructions concerning premedication.
-Do not mix elotuzumab with, or administer an infusion with, other medicinal products.
Use: In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Liver enzymes should be monitored and dosing should be adjusted if warranted.
-If the dose of one drug in the regimen is delayed, interrupted, or discontinued, the treatment with the other drugs may continue as scheduled. However, if dexamethasone is delayed or discontinued, the decision on whether to administer elotuzumab should be based on clinical judgment (i.e., risk of hypersensitivity).
-If a Grade 2 or higher infusion reaction occurs during elotuzumab administration, interrupt the infusion and institute appropriate medical and supportive measures. Upon resolution to Grade 1 or lower, restart elotuzumab at 0.5 mL per minute and gradually increase at a rate of 0.5 mL per minute every 30 minutes as tolerated to the rate at which the infusion reaction occurred. Resume the escalation regimen if there is no recurrence of the infusion reaction.
-Adjust the infusion rate following a Grade 2 or higher infusion reaction.
-For patients who have received 4 cycles of treatment, the infusion rate may be increased to a maximum of 5 mL/min.
-Vital signs should be monitored every 30 minutes for 2 hours after the end of the infusion in patients who experience an infusion reaction.
-If the infusion reaction recurs, stop the infusion and do not restart on that day.
-Severe infusion reactions may require permanent discontinuation of therapy and emergency treatment.
-Dose delays and modifications for dexamethasone and lenalidomide should be performed as recommended in their manufacturer prescribing information.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
This drug is not removed by dialysis.
-The manufacturer product information should be consulted.
-Store under refrigeration at 2C to 8C (36F to 46F).
-Protect from light by storing in the original package until time of use.
-Do not freeze or shake.
-Instruct the patient to read the approved patient labeling.
More about elotuzumab
- Other brands: Empliciti